| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1701-2163(15)31025-2 |
| P698 | PubMed publication ID | 23470070 |
| P2093 | author name string | Sylvie Langlois | |
| Jo-Ann Brock | |||
| GENETICS COMMITTEE | |||
| P2860 | cites work | Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood | Q24657306 |
| Noninvasive prenatal diagnosis of fetal trisomy 18 and trisomy 13 by maternal plasma DNA sequencing | Q28742844 | ||
| DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study | Q30414408 | ||
| DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study | Q34029044 | ||
| Prenatal Detection of Down Syndrome using Massively Parallel Sequencing (MPS): a rapid response statement from a committee on behalf of the Board of the International Society for Prenatal Diagnosis, 24 October 2011. | Q34249522 | ||
| Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing | Q34256640 | ||
| Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study | Q34482155 | ||
| Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study | Q36538133 | ||
| Non-invasive diagnosis of fetal sex; utilisation of free fetal DNA in maternal plasma and ultrasound | Q36541744 | ||
| Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma | Q37010246 | ||
| The use of cell-free fetal nucleic acids in maternal blood for non-invasive prenatal diagnosis | Q37306246 | ||
| Noninvasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18. | Q40028555 | ||
| Optimal detection of fetal chromosomal abnormalities by massively parallel DNA sequencing of cell-free fetal DNA from maternal blood | Q44645735 | ||
| Noninvasive prenatal diagnosis of common fetal chromosomal aneuploidies by maternal plasma DNA sequencing. | Q46892061 | ||
| Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. | Q51349861 | ||
| Maternal plasma DNA analysis with massively parallel sequencing by ligation for noninvasive prenatal diagnosis of trisomy 21. | Q53063252 | ||
| Chromosome-selective sequencing of maternal plasma cell–free DNA for first-trimester detection of trisomy 21 and trisomy 18 | Q61847821 | ||
| Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population | Q61847837 | ||
| Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting | Q83395075 | ||
| P433 | issue | 2 | |
| P921 | main subject | Down syndrome | Q47715 |
| P304 | page(s) | 177-181 | |
| P577 | publication date | 2013-02-01 | |
| P1433 | published in | Journal of Obstetrics and Gynaecology Canada | Q15761143 |
| P1476 | title | Current status in non-invasive prenatal detection of Down syndrome, trisomy 18, and trisomy 13 using cell-free DNA in maternal plasma | |
| P478 | volume | 35 |
| Q43083929 | A case of placental trisomy 18 mosaicism causing a false negative NIPT result |
| Q34426839 | Cell-free nucleic acids as non-invasive biomarkers of gynecological cancers, ovarian, endometrial and obstetric disorders and fetal aneuploidy |
| Q38959581 | Changing to NIPT as a first-tier screening test and future perspectives: opinions of health professionals |
| Q38418240 | Clinical implementation of NIPT - technical and biological challenges |
| Q92312439 | Cost-Effectiveness Analysis of Non-invasive Prenatal Testing for Down Syndrome in China |
| Q35667103 | Counseling Challenges with Variants of Uncertain Significance and Incidental Findings in Prenatal Genetic Screening and Diagnosis |
| Q89495628 | Differential expression profile study and gene function analysis of maternal foetal-derived circRNA for screening for Down's syndrome |
| Q35900347 | Expanding diagnostic testing beyond cytogenetics: implications for birth defects research and surveillance |
| Q41592901 | First trimester contingent testing with either nuchal translucency or cell-free DNA. Cost efficiency and the role of ultrasound dating |
| Q44729421 | First-trimester Down syndrome screening using additional serum markers with and without nuchal translucency and cell-free DNA. |
| Q40524568 | Frequency of fetal karyotype abnormalities in women undergoing invasive testing in the absence of ultrasound and other high-risk indications. |
| Q27003962 | Identification of trisomy 18, trisomy 13, and Down syndrome from maternal plasma |
| Q26764748 | Improving Decision Making about Genetic Testing in the Clinic: An Overview of Effective Knowledge Translation Interventions |
| Q36402612 | Incorporation of dried blood alpha fetoprotein into traditional first trimester Down syndrome screening service. |
| Q36787475 | Integration of noninvasive DNA testing for aneuploidy into prenatal care: what has happened since the rubber met the road? |
| Q38730837 | Making genomic medicine evidence-based and patient-centered: a structured review and landscape analysis of comparative effectiveness research |
| Q43872436 | Maternal cfDNA screening for Down syndrome--a cost sensitivity analysis |
| Q35142853 | Model-based analysis of costs and outcomes of non-invasive prenatal testing for Down's syndrome using cell free fetal DNA in the UK National Health Service |
| Q26827338 | Non-Invasive Prenatal Testing Using Cell Free DNA in Maternal Plasma: Recent Developments and Future Prospects |
| Q36184534 | Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening |
| Q38114375 | Non-invasive prenatal testing for aneuploidy: current status and future prospects |
| Q26764809 | Non-invasive prenatal testing for fetal chromosome abnormalities: review of clinical and ethical issues |
| Q51074981 | Non-invasive prenatal testing: ethics and policy considerations. |
| Q52837725 | Noninvasive prenatal testing and fetal sonographic screening: roundtable discussion. |
| Q39149988 | Noninvasive prenatal testing by maternal plasma DNA analysis: current practice and future applications |
| Q37338477 | Not-so-free testing for cell-free DNA. |
| Q56769559 | Physician liability and non-invasive prenatal testing |
| Q93265239 | Physicians' perception toward non-invasive prenatal testing through the eye of the Rogers' diffusion of innovation theory in China |
| Q35237602 | Prenatal invasive procedures in women with hepatitis B, hepatitis C, and/or human immunodeficiency virus infections |
| Q58106679 | Printing Unrealistic Expectations: A Closer Look at Newspaper Representations of Noninvasive Prenatal Testing |
| Q46624086 | QF-PCR rapid aneuploidy screen and aCGH analysis of cell free fetal (cff) DNA in supernatant of compromised amniotic fluids (AF). |
| Q38179321 | Role of the second-trimester 'genetic sonogram' for Down syndrome screen in the era of first-trimester screening and noninvasive prenatal testing |
| Q30699635 | Selected birth defects data from population-based birth defects surveillance programs in the United States, 2006 to 2010: featuring trisomy conditions |
| Q86625307 | Survey of the Definition of Fetal Viability and the Availability, Indications, and Decision Making Processes for Post-Viability Termination of Pregnancy for Fetal Abnormalities and Health Conditions in Canada |
| Q87298407 | The Integration of Noninvasive Prenatal Screening into the Existing Prenatal Paradigm: a Survey of Current Genetic Counseling Practice |
| Q86800597 | The Latest Thorn by Any Other Name: Germ-Line Nuclear Transfer in the Name of "Mitochondrial Replacement" |
| Q46271940 | The clinical utility of DNA-based screening for fetal aneuploidy by primary obstetrical care providers in the general pregnancy population |
| Q51125785 | The price of performance: a cost and performance analysis of the implementation of cell-free fetal DNA testing for Down syndrome in Ontario, Canada. |
| Q60912472 | The value of non-invasive prenatal testing: preferences of Canadian pregnant women, their partners, and health professionals regarding NIPT use and access |
| Q37067727 | Uptake, outcomes, and costs of implementing non-invasive prenatal testing for Down's syndrome into NHS maternity care: prospective cohort study in eight diverse maternity units |
| Q58301130 | What Is “NIPT”? Divergent Characterizations of Noninvasive Prenatal Testing Strategies |
| Q38996878 | Women's Experiences of Publicly Funded Non-Invasive Prenatal Testing in Ontario, Canada: Considerations for Health Technology Policy-Making |
Search more.